Arena Optimistic About Lorcaserin But Analysts More Reserved
This article was originally published in The Pink Sheet Daily
Executive Summary
Arena Pharmaceuticals argues it has the necessary safety data to convince an FDA advisory committee to recommend approval of its key drug, a weight loss treatment.
You may also be interested in...
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
Arena Pharmaceuticals has won an early race against Vivus and Orexigen Therapeutics in finding a commercialization partner for its obesity drug candidate lorcaserin. The three companies are vying to bring the first new obesity drug to the market in over a decade, with U.S. FDA action dates for the three candidates scheduled between October and January